Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors

Hsu, Hui-TeHui-TeHsuYu, Chu-ChunChu-ChunYuYUN-HSIANG LEEChan, Jui-ChunJui-ChunChanCHIA-YU CHU2022-09-192022-09-192022-09-030941-4355https://scholars.lib.ntu.edu.tw/handle/123456789/621162Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are frequently associated with dermatologic adverse events (dAEs), having great impacts on patients' health-related quality of life (HRQoL) and treatment adherence. We aimed to examine the association between various dAEs and HRQoL in patients treated with EGFR-TKI therapy.enAdverse events; Epidermal growth factor receptor-tyrosine kinase inhibitors; Lung cancer; Osimertinib; Paronychia; Quality of life[SDGs]SDG3Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitorsjournal article10.1007/s00520-022-07347-1360569412-s2.0-85137420220WOS:000849474700001https://api.elsevier.com/content/abstract/scopus_id/85137420220